NCCN News

NCCN Publishes Comprehensive Stage-Specific Breast Cancer Resources for Patients

NCCN, with the support of the NCCN Foundation, announces the availability of the NCCN Guidelines for Patients: Breast Cancer Stages 0 - IV, which is the latest addition to the library of NCCN Guidelines for Patients available online free-of-charge at NCCN.org/patients. This is the first comprehensive stage-specific library of NCCN Guidelines for Patients published by NCCN.

The NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), are designed to provide state-of-the-art treatment information in easy-to-understand language to people with cancer and their caregivers.

NCCN Guidelines for Patients: Breast Cancer was originally published in 2010; NCCN Guidelines for Patients: Stage 0 Breast Cancer—the first stage-specific installment of NCCN Guidelines for Patients—was made available in November 2013.

“NCCN is pleased to be able to offer patients and their caregivers a trusted, comprehensive, and concise educational resource for breast cancer treatment,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “Given the incredible amount of information that is publicly available about breast cancer, the stage-specific NCCN Guidelines for Patients: Breast Cancer offer patients a more personalized approach to their disease, empowering them to make well-informed decisions about their treatment.”

Visit NCCN.org/patients for the library of NCCN Guidelines for Patients, as well as other patient and caregiver resources.

Now Available! Recorded Presentations from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™

Recorded activities from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care, held March 13-15, 2014, in Hollywood, Florida, which are designed to meet the educational needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer, are now available at education.nccn.org/ac2014.

The NCCN Annual Conference attracts more than 1500 registrants from across the United States and around the world, including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), the data on which the NCCN Guidelines are based, and quality initiatives in oncology. Topics change annually, but focus on the major cancers and supportive care areas. The NCCN Annual Conference also includes case study discussion forums with experts from NCCN Member Institutions and roundtable discussions featuring the foremost professionals from the academic, patient advocacy, government, payer, industry, and business realms of cancer care.

The activities listed below are approved for AMA PRA Category 1 Credit(s). Nursing and pharmacy (ACPE) credits may also be provided. Please refer to the complete accreditation information provided before the individual educational activity for more details.

Breast Cancer

  • Treatment of Metastatic Breast Cancer

Hematologic Malignancies

  • Developments in the Treatment of Multiple Myeloma
  • Guidelines for NHL: Updates to the Management of DLBCL and New Guidelines for T-Cell Lymphoproliferative Disorders
  • Monitoring Molecular Response to TKI Therapy in Chronic Myelogenous Leukemia
  • Therapeutic Advances in the Treatment of CLL: Focus on Inhibitors of the BCR Signaling Pathways

Skin Malignancies

  • Melanoma Guideline Update: New Agents and Opportunities for Treatment
  • Optimal Treatment of Unresectable Nonmelanoma Skin Cancers
  • Targeted Agents: Management of Dermatologic Toxicities

Supporters:

Breast Cancer

Supported by educational grants from AstraZeneca; Eisai Inc.; Genentech; and Novartis Oncology.

Hematologic Malignancies

Supported by educational grants from Bristol-Myers Squibb; Millennium: The Takeda Oncology Company; Novartis Oncology; and Spectrum Pharmaceuticals, Inc.; and by a grant from Onyx Pharmaceuticals.

Skin Malignancies

Supported by educational grants from Genentech and Prometheus Laboratories, Inc.

Free NCCN Pocket Guidelines Available for Antiemesis

NCCN is pleased to offer a pocket-sized version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis. This printed version of the NCCN Guidelines is conveniently sized to fit in a lab coat pocket and serve as a valuable reference for physicians, nurses, pharmacists, and other oncology health care professionals.

These pocket guidelines booklets are printed on quality gloss stock for durability and have coil spines so that algorithms can be viewed as 2-page spreads. Content is formatted in sections with colored tabs so readers can quickly and easily reference desired sections.

Thanks to generous sponsorship, NCCN will supply and ship up to 5 copies of the NCCN pocket guidelines for Antiemesis for free. Requests can be made for additional copies.

NCCN pocket guidelines are also available for Multiple Myeloma and Myelodysplastic Syndromes.

NCCN pocket guidelines are available for free while supplies last. To order, visit NCCN.org/onlinecatalog.


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 61 6 0
PDF Downloads 3 1 0
EPUB Downloads 0 0 0